Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Gossamer Bio (NASDAQ:GOSS - Free Report) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Separately, Wedbush reissued an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio has a consensus rating of "Buy" and a consensus price target of $9.20.

Gossamer Bio Price Performance

Gossamer Bio stock traded down $0.02 during trading hours on Monday, hitting $0.86. 800,060 shares of the company traded hands, compared to its average volume of 1,432,600. The firm has a market cap of $194.15 million, a P/E ratio of -2.68 and a beta of 1.96. The company has a quick ratio of 8.21, a current ratio of 8.21 and a debt-to-equity ratio of 2.42. The firm's 50-day simple moving average is $0.94 and its two-hundred day simple moving average is $0.86. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. As a group, analysts forecast that Gossamer Bio will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC grew its stake in shares of Gossamer Bio by 51.6% in the 1st quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company's stock worth $3,227,000 after purchasing an additional 931,248 shares during the last quarter. Marshall Wace LLP increased its position in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company's stock worth $3,002,000 after acquiring an additional 2,103,766 shares in the last quarter. NEA Management Company LLC increased its position in shares of Gossamer Bio by 14.2% in the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company's stock worth $16,300,000 after acquiring an additional 2,255,025 shares in the last quarter. Monaco Asset Management SAM increased its position in shares of Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company's stock worth $2,456,000 after acquiring an additional 2,170,104 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in shares of Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company's stock worth $84,000 after acquiring an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.